As a drug discovery venture originating from Kyoto University, we are developing RN-501, a novel boron-containing drug for boron-neutron capture therapy (BNCT), a next-generation cancer radiation therapy targeting intractable cancers. Through proprietary boron carbide nanoparticle technology and polyglycerol modification, RN-501 achieves high tumor selectivity and accumulation, along with potent cancer-killing and immune-activating effects with a single intravenous administration, overcoming the limitations of existing drugs. As Japan's first and the world's first nano-BNCT drug, we aim for early societal implementation.
RadioNano Therapeutics株式会社（本社：京都市左京区、代表取締役社長 千葉雅俊）は、先進的な研究開発で事業化を目指す企業を応援、社会課題／地域課題の解決に資する先進的な研究開発プランのサポートを通じ...
RadioNano Therapeutics株式会社（本社：京都市左京区、代表取締役社長 千葉雅俊）は、京都キャピタルパートナーズ株式会社の運営するKCAPベンチャー1号投資事業有限責任組合、中信ベンチャーキャピタル株式会社...
NUProtein develops next-generation protein and bioactive compound production technologies using genetically engineered rice. By cultivating high-expression rice and extracting target components directly from the grain, the company achieves exceptionally low-cost and stable production compared with conventional methods. NUProtein is also recognized as one of the world’s five industrial players in cell-free protein synthesis and gene-related patents. Through low-cost growth factors and other functional proteins, the company is building a new supply chain for the cultivated meat and broader food-tech sectors.
A startup originating from the University of Tokyo and the University of Tsukuba, possessing proprietary technology for selectively amplifying hematopoietic stem cells in vitro. It aims to realize next-generation regenerative medicine through cell and gene therapies for blood disorders and genetic diseases, as well as vascular regeneration technology.
bacterico is a biotechnology startup developing personalized healthcare solutions based on an individual’s own gut microbiome. We isolate, select, and cultivate Bifidobacterium strains from stool samples and enhance them using proprietary culture methods to create personalized probiotic supplements optimized for each person’s gut environment. We also provide evidence-based programs tailored to key life moments, including Mama Flora, which supports maternal and infant health through prenatal gut microbiome care, and Preflora, a personalized nutrition and gut-health program designed specifically for individuals who are actively trying to conceive. Through science-driven, individualized interventions, bacterico aims to bring safe and effective microbiome-based solutions to everyday health.
A startup leveraging its proprietary language processing technology, SATOMI®, to support the automatic generation of medical records and referral letters. By streamlining information use in clinical settings, it promotes regional collaboration and medical DX, contributing to the development of a sustainable healthcare system.